Cladribine s.c. injection, HCL treatment

Small molecule

Cladribine s.c. injection, HCL treatment is one of 28 small molecule programs targeting Hairy Cell Leukemia. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hairy Cell LeukemiaActive, not recruiting

Hairy Cell LeukemiaPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

33 competitors in Hairy Cell Leukemia

#DrugCompanyPhaseTrials

Braftovi

Rituxan

7 3

Gazyva

Roche

Phase 2

2 4

Venclexta

AbbVie

Phase 2

1 5

Nipent

Pfizer

Phase 2

1 6

Mektovi

Pfizer

Phase 2

1 7

Leustatin

EMD Serono

Phase 2

4 8

Roferon-a

Roche

Phase 2

—9

Zelboraf

CConrado Roberto Hoffmann Filho

Phase 2

3 10

Tylenol

KKenvue Brands

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2/3Recruiting

Hairy Cell Leukemia

NCT02131753

Clinical

Trials by Indication[1]

Hairy Cell Leukemia1 trial

Therapy Optimisation for the Treatment of Hairy Cell Leukemia

Recruiting·UUniversity of Giessen·Phase 2/3·NCT02131753·210 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cladribine s.c. injection, HCL treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cladribine s.c. injection, HCL treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cladribine s.c. injection, HCL treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Giessen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: UUniversity of Giessen

Cladribine s.c. injection, HCL treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Hairy Cell Leukemia1 trial

References

Drug Info

Quick Facts

Related News